Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.39 |
| ▸ | MTOR | P42345 | 6/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5889174 | 0.85 | HRH4 (0.40) | LRRK2HRH4RIPK1P4HTMBTK | |
| SCHEMBL2075565 | 0.82 | HRH4 (0.52) | LRRK2HRH4RIPK1P4HTMBTK | |
| SCHEMBL2076114 | 0.81 | HRH4 (0.54) | LRRK2HRH4P4HTMBTKMAP4K4 | |
| SCHEMBL6797898 | 0.77 | AKT1 (0.42) | LRRK2SMN1; SMN2HRH4PIK3CAMTOR | |
| SCHEMBL30068105 | 0.77 | AKT1 (0.42) | LRRK2SMN1; SMN2HRH4PIK3CAMTOR | |
| SCHEMBL20241721 | 0.75 | PIK3CA (0.42) | LRRK2SMN1; SMN2HRH4PIK3CAMTOR | |
| SCHEMBL5889102 | 0.74 | KDR (0.66) | LRRK2 | |
| SCHEMBL17840362 | 0.71 | SMN1; SMN2 (0.51) | SMN1; SMN2MAPT | |
| SCHEMBL807737 | 0.71 | HRH4 (0.59) | HRH4MAPTMAP4K4 | |
| SCHEMBL16371441 | 0.70 | DGAT1 (0.43) | LRRK2DGAT1PIK3CAMTORMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115597-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040063720-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-04-01 | — | — | US | disclosed |
| US-20020137755-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137755-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | LRRK2 185/4885SMN1; SMN2 4473/4885DGAT1 1697/4885 |
| US-20040063720-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | LRRK2 185/4885SMN1; SMN2 4473/4885DGAT1 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.